Clinical Trial Update: Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study assessing potential drug-drug interaction between VX-809 (lumacaftor) and VX-770 (ivacaftor) in healthy subjects; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• VX-770 (ivacaftor)
• VX-809 (lumacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 1 | Status: COMPLETED